The next phase of Genshin Impact Version 5.7 begins on July 8th. That means players only have a few more days to pull on current banners before they switch over. Starting with the Phase 2 update, ...
BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...
A once-weekly injectable GIP/GLP-1 dual agonist conferred up to 22.5% weight loss at 48 weeks for adults with overweight or ...
The Chosun Ilbo on MSN
Roche's obesity drug shows 22.5% weight loss in phase 2 trials
Swiss pharmaceutical company Roche announced on the 27th (local time) that its obesity treatment pipeline ‘CT-388’ recorded a ...
Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients
Novo Nordisk A/S (NYSE: NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes. The update marks the first evaluation of amycretin in people with type 2 ...
Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile consistent with previous studies, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results